regulatory
confidence high
sentiment negative
materiality 0.80
LIFECORE BIOMEDICAL, INC. DE (LFCR): Nasdaq/NYSE listing notice — Lifecore Biomedical receives Nasdaq notice for delayed quarterly and annual filings
LIFECORE BIOMEDICAL, INC. DE
- Nasdaq notified Lifecore on Jan 10, 2024 that it is not compliant with Listing Rule 5250(c)(1) due to delayed Q2 Form 10-Q and continued delays in Form 10-K and Q1 Form 10-Q.
- The company had a previously approved compliance plan with an exception period until Feb 12, 2024 to file Form 10-K and Q1 Form 10-Q.
- Lifecore plans to submit an updated compliance plan by Jan 25, 2024 to address the Q2 Form 10-Q filing and regain compliance.
- The notice has no immediate effect on the listing or trading of LFCR common stock on Nasdaq Global Select Market.
- The company continues to work to complete the filings but cannot assure regaining compliance by the deadline.